Krystal Biotech, Inc. (KRYS) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US5011471027
Krystal Biotech, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 389.13 m USD |
| Operating income | 161.30 m USD |
| EBIT | 189.47 m USD |
| Net income | 204.83 m USD |
| Diluted EPS – continuing operations | 6.84 USD |
Full history since 2016, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Krystal Biotech, Inc.
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
More stocks
- Ackermans & Van Haaren NV (ACKB.BR)
- Ivanhoe Mines Ltd (IVN.TO)
- ADVANCED ENERGY INDUSTRIES INC (AEIS)
- Eneva S.A (ENEV3.SA)
- Gitlab Inc. (GTLB)
- Match Group, Inc. (MTCH)
- ZIONS BANCORPORATION, NATIONAL ASSOCIATION /UT/ (ZION)
- Poly Real Estate Group Co Ltd (600048.SS)
- Xizang Haisco Pharmaceutical Group Co Ltd (002653.SZ)
- Allwyn AG (ALWN.AT)
- China Oilfield Services Ltd Class A (601808.SS)
- LITTELFUSE INC /DE (LFUS)
Not investment advice. All data without warranty, price as of 22.10.2026. Details in the risk notice.